Introduction: Statins, in the role of anti-cancer agents, have been used in many types of cancers with results in some cases promising while, in others, disappointing. Areas covered: The purpose of this review is to identify and highlight data from literature on the successes or failure of using statins as anti-cancer agents. We asked ourselves the following two questions: 1. Could statins, which are taken mostly to reduce cardiovascular risk, guarantee a lower incidence or a better cancer disease prognosis, concerning local recurrence, metastasis or mortality? 2. Does statins intake (before and/or after cancer diagnosis) improve the prognosis or increase the chemotherapeutic action when combined with other anticancer therapies? For the first question twenty-seven manuscripts have been selected, for the second one, twenty-eight. Expert opinion: There are data which correlate statins with a possible tumor suppressive action among the following cancers: breast, lung, prostate and head and neck. Lastly, for gastric cancer and colorectal there is no evidence of a correlation. The onco-suppressive efficacy of statins is mainly related to the histopathological and/or molecular characteristics of the tumor cells, which have different characteristics.
Are statins onco- suppressive agents for every type of tumor? A systematic review of literature / Filaferro, Luca; Zaccarelli, Fabiana; Niccolini, GIOVANNI FRANCESCO; Colizza, Andrea; Zoccali, Federica; Grasso, Michele; Fusconi, Massimo. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - (2024), pp. 1-11. [10.1080/14737140.2024.2343338]
Are statins onco- suppressive agents for every type of tumor? A systematic review of literature
Luca FilaferroPrimo
Data Curation
;Fabiana ZaccarelliSecondo
Formal Analysis
;Giovanni Francesco NiccoliniFormal Analysis
;Andrea ColizzaWriting – Review & Editing
;Federica ZoccaliWriting – Original Draft Preparation
;Massimo Fusconi
Ultimo
Conceptualization
2024
Abstract
Introduction: Statins, in the role of anti-cancer agents, have been used in many types of cancers with results in some cases promising while, in others, disappointing. Areas covered: The purpose of this review is to identify and highlight data from literature on the successes or failure of using statins as anti-cancer agents. We asked ourselves the following two questions: 1. Could statins, which are taken mostly to reduce cardiovascular risk, guarantee a lower incidence or a better cancer disease prognosis, concerning local recurrence, metastasis or mortality? 2. Does statins intake (before and/or after cancer diagnosis) improve the prognosis or increase the chemotherapeutic action when combined with other anticancer therapies? For the first question twenty-seven manuscripts have been selected, for the second one, twenty-eight. Expert opinion: There are data which correlate statins with a possible tumor suppressive action among the following cancers: breast, lung, prostate and head and neck. Lastly, for gastric cancer and colorectal there is no evidence of a correlation. The onco-suppressive efficacy of statins is mainly related to the histopathological and/or molecular characteristics of the tumor cells, which have different characteristics.File | Dimensione | Formato | |
---|---|---|---|
Filaferro_Are statins_2024.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
656.42 kB
Formato
Adobe PDF
|
656.42 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.